Abstract: Disclosed are a pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of RNA binding protein and applications thereof, in particular the application in the treatment of ALS. The pharmaceutical composition can significantly enhance the dynamic performance of stress particles containing RNA binding proteins such as hnRNP A1 and TDP-43 proteins; influences the interaction between the RNA binding proteins and other poly ADP ribosylation modified proteins or other PAR binding proteins; influences the subcellular localization and stress response of RNA binding proteins; influences the liquid-liquid phase separation and aggregation tendency of RNA binding proteins; influences the co-phase separation between RNA binding proteins; influences the interaction of RNA binding proteins in cells; and has a significant inhibitory effect on neurotoxicity caused by RNA binding proteins.

Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide. eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.

Abstract: A pharmaceutical composition is provided comprising combination of antiretroviral drugs optionally in combination of pharmacokinetic boosters. The formulation is used for the treatment of diseases caused by retroviruses. The process of preparation of the formulation is also provided.

Abstract: Compounds, compositions, and methods of treatment and prevention of Hepacivirus, Pestivirus, Flavivirus or Alphavirus infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of Hepacivirus, Pestivirus, Flavivirus or Alphavirus in an infected patient.

Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.

Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).

Abstract: In some aspects, the present disclosure provides germ cell nuclear factor ligands of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions and methods of use thereof. Also provided are cell cultures and cell culture media comprising the GNCF ligands of the present disclosure as well as methods of use thereof.

Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.

Abstract: Formulations of lixivaptan, and methods of using the same, are provided for the treatment of polycystic disease.

Abstract: The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

Abstract: Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.

Abstract: Provided herein are oral drug preparations including cyproterone acetate and ethinylestradiol, dosing regimen for the drug preparations, and methods of treating diseases. The methods provided include the administration of the oral drug preparation to treat one or more symptoms of hyperandrogenic conditions or hyperandrogenic activities, to provide contraception, and to reduce a risk of vascular thromboembolism (VTE) in a subject.

Abstract: This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.

Abstract: Provided herein are methods for treating a sleep disorder, e.g., insomnia, in a subject, comprising administering to the subject an effective amount of a compound having the formula (Compound 1) or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

Abstract: The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl) propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.

Abstract: There are disclosed therapies and preventions of prion protein complex infections. The transcription of the amyloid precursor protein gene and PrP gene and the RNA transcript are the rate-limiting steps and are most susceptible for blockage and control of the process of amyloid protein formation and PrPsc formation. Thus, therapies and prevention regimes for prion protein complex infections interrupt this process at the level of DNA transcription to RNA, RNA transport to the mitochondrion for protein synthesis and deposition in the cerebral cortex neurons.

Abstract: A method of treating a human papillomavirus (HPV)-induced cancer in a subject in need of such treatment by administering to the subject an effective amount of an inhibitor of Inhibitor of Nuclear Factor kappa-B kinase subunit beta (IKK?). A method of inhibiting growth of human papillomavirus (HPV)-induced cancer cells, in vivo or in vitro, comprising exposing the cells to an inhibitor of Inhibitor of Nuclear Factor kappa-B kinase subunit beta (IKK?).

Abstract: The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, postnatal development, and during development in the adult, organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function.

Abstract: Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.

Abstract: Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.

Abstract: The disclosure relates to a pectin-adriamycin conjugate, and discloses a preparation method and use of the conjugate above. The pectin-adriamycin conjugate of the disclosure has a completely new chemical structure and can be accumulated in a malignant tumor tissue for a long time with a high concentration in a targeting manner so as to achieve the purposes of enhancing effects and reducing toxicity, and the indications are chemotherapies of various solid malignant tumors.

Abstract: This invention relates to methods and compositions for administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine. In particular, the invention relates to methods for treating cancer, inhibiting degradation of a CDA substrate drug, and reducing DNA methylation in a subject in need thereof comprising administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine.

Abstract: Polymeric compositions are provided that include a poly(ethylene glycol), a viscoelastic polymer, and an antioxidant, where, in polymerized form, the compositions have a refractive index of about 1.30 to about 1.40. Methods of synthesizing the compositions are also provided and include the steps of heating an amount of water; adding a buffering agent to the water to form a buffer solution; mixing a poly(ethylene glycol) and a viscoelastic polymer into the buffer solution to form a reactive mixture; adding a plurality of antioxidant particles to the reactive mixture; and removing suspended gas bubbles from the reactive mixture. Methods of preventing oxidative damage to an eye lens of a subject are further provided and include administering the foregoing polymeric compositions to the eye lens of the subject.

Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract: Analogues of oleuropein and oleacein and pharmaceutically acceptable salts thereof and processes for the preparation of these compounds are disclosed. The invention further relates to use of oleuropein and oleacein analogues for the treatment of inflammatory disorders, cardiometabolic disorders, and cancer.

Abstract: Provided herein are reverse transcriptase (RT) blocking agents and methods of using the same for the treatment of cancer (e.g., an epithelial cancer) in a subject in need thereof.

Abstract: A composition according to an embodiment includes porous silica particles carrying nucleic acid molecules that complementarily bind to at least a portion of thymic stromal lymphopoietin (TSLP) mRNA. The composition is capable of preventing or treating, with excellent efficiency, atopic diseases, such as bronchial asthma, allergic rhinitis, atopic dermatitis, allergic dermatitis or inflammatory skin diseases by effectively inhibiting the expression level of TSLP.

Abstract: This document provides methods and materials for treating diabetes and/or liver steatosis. For example, methods for using compositions containing a potato polysaccharide preparation to reduce one or more symptoms of diabetes or liver steatosis are provided.

Abstract: This disclosure relates to mRNA therapy for the treatment of very long-chain specific acyl-CoA dehydrogenase deficiency (VLCADD). mRNAs for use in the invention, when administered in vivo, encode human very long-chain specific acyl-CoA dehydrogenase (VLCAD). mRNA therapies of the disclosure increase and/or restore deficient levels of VLCAD expression and/or activity in subjects. mRNA therapies of the disclosure further decrease abnormal accumulation of acylcarnitine associated with deficient VLCAD activity in subjects.

Abstract: Disclosed in certain embodiments are skincare formulations and treatment methods having hyaluronic acid, or its associated salts, and one or more of ascorbic acid, glycolic acid or lactic acid. In certain embodiments, the formulations and treatments are applied to the skin during and/or before and/or after dermatological procedures that affect the skin's barrier for alleviating patient discomfort and enabling rapid healing of irritated and damaged skin.

Abstract: The present invention provides stable antimicrobial and disinfectant compositions comprising use of a solid precursor of an oxidized state of chlorine. The invention also provides on-demand storage and mixing vessels and methods for preparing and delivering on demand formulations. In addition, the invention provides antiviral, antibiotic and general antimicrobial uses, in vivo, on surfaces and via spray applications.

Abstract: A ready-to-use (RTU) potassium phosphates in sodium chloride solution for phosphorus replacement therapy includes potassium phosphate and sodium chloride at a fixed volume with 15 mmol/100 mL phosphorus and 22 mEq/100 mL potassium and less than 50 mcg/L aluminum.

Abstract: Provided herein is an engineered extracellular vesicle (eEV) and an extracellular vesicle delivery vehicle. The engineered extracellular vesicle is an isolated extracellular vesicle that has a membrane hybridized with lipids. The extracellular vesicle delivery vehicle is a lipid-hybridized extracellular vesicle with a nucleic acid loaded within the core, a multi-layered polyelectrolyte coating deposited around the lipid-hybridized extracellular vesicle and a therapeutic drug complexed to one of the layer of polyelectrolyte coatings. Also provided are methods for preparing an engineered extracellular vesicle, for preparing an extracellular vesicle delivery vehicle, for treating a pathophysiological condition in a subject, and for co-delivering a nucleic acid and a therapeutic drug to a cell of interest.

Abstract: Compositions, methods of use, and pharmaceutical preparations useful for modulation of immune responses are disclosed herein. In one embodiment a composition is extracted from immune organs or leukocytes derived from members of the chondrichthyes family through dialysis. Said immune modulator is useful for treatment of conditions requiring stimulations or regulation of immunity. In one embodiment, said immunomodulator controls T cell activation by modulation of cytokine production.

Abstract: The novel coronavirus COVID-19 has caused a worldwide pandemic of enormous proportions resulting in significant levels of morbidity and mortality, tremendous pressures on the healthcare system, personal freedoms and society, and an unprecedented impact on the economies of the United States and the world. There are still significant unknowns about this very contagious and deadly virus, and these unknowns are coupled with no natural immunity. A promising therapeutic strategy is the utilization/transfusion of convalescent plasma from recovered COVID-19 patients. There are, however, risks involved in such transfusions from residual virus and other adventitious viruses and bacteria. These risks can be minimized by the pathogen clearance of convalescent plasma units in a hospital setting. There is an immediate need for the rapid pathogen inactivation/clearance of convalescent plasma units from recovered COVID-19 patients.

Abstract: Provided in the present invention are a composition of immune effector cells and a treatment kit including the composition of immune effector cells, wherein the composition of immune effector cells comprises an initial dose of immune effector cells and a subsequent dose of immune effector cells.

Abstract: The present disclosure provides methods and compositions related to the modification of Tregs to increase therapeutic efficacy. In some embodiments, Tregs modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance immunosuppressive functions of the immune cells are provided. In some embodiments, Tregs further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating an autoimmune diseases using the modified Tregs described herein are also provided.

Abstract: This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, materials and methods for producing a T cell comprising a FOXP3 polypeptide and a microRNA are provided herein. Also provided are methods of treating an autoimmune disease that include administering these T cells.

Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.

Abstract: A pretreatment herbal composition comprises Andrographis paniculata, Eleuthero roots, and resistant potato starch. A treatment herbal composition comprises cannabidiol, bee pollen, and coconut oil, and in some embodiments, additionally comprises hemp seed oil. A fortifying herbal composition comprises many ingredients. A method comprises the steps of providing a dose of apitoxin at least once a day for at least one day, providing a dose of a glucosamine product at least once a day for at least one day, and providing a dose of a treatment herbal composition at least once a day for at least one day. In some embodiments, the method additionally comprises the step of providing a dose of a pretreatment herbal composition at least once a day for at least one day. In further embodiments, the method additionally comprises the step of providing a dose of a fortifying herbal composition.

Abstract: Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof.

Abstract: Disclosed are compositions, systems and methods comprising a regenerative fibroblast cell, population or subsets thereof possessing regenerative activity useful for treatment of various degenerative diseases. In one embodiment, the disclosure provides fibroblasts with enhanced proliferative potential based on enrichment for CD105 and/or CD117 markers. In one embodiment, fibroblasts possessing CD105 and/or CD117 markers are further enriched for the property of rhodamine 123 efflux.

Abstract: This invention relates to a method for repairing and reconstructing a damaged or non-functional muscle, in particular to a method and a tool kit using in vitro primed motor endplate-expressing muscle progenitor cells (MPCs) to promote innervation of the damaged or non-functional muscle using an agent without any genetic manipulation. This method is particularly useful for repairing or reconstructing damaged or non-functional head and neck muscles, and urinary detrusor bladder muscle.

Abstract: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.

Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxis and that caused by insufficient blood supply. In some further particulars the invntion relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children, for example, and to the treatment of cortical infants and stroke with MAPCs in adults, for example.

Abstract: The invention relates to processes for producing semi-purified and purified allergen extracts and pharmaceutical compositions and vaccines for use in the diagnosis and treatment of allergy. In one aspect of the invention, a process for producing a depigmented allergen extract is provided, the process comprising: a) basifying a native allergen extract; and b) removing molecules having a molecular size of less than 3.5 kDa; and c) adjusting the pH to neutrality; thereby to produce a depigmented allergen extract.

Abstract: The present disclosure discloses application of D. newyorkensis in prolonging lifespan and anti-aging, and belongs to the technical fields of biomedicine and microorganisms. The D. newyorkensis NYU-BL-A4 used in the present disclosure can prolong the lifespan of C. elegans without affecting the normal vital sign of swallowing frequency of C. elegans, is safe and has no toxic and side effects to the nematodes. Therefore, it can have a good anti-aging effect and can be applied to the preparation of anti-aging and life-prolonging products.

Abstract: The invention pertains to a nutritional composition for infants or young children comprising 2?fucosyllactose, and 3?galactosyllactose, and preferably dietary butyric acid.